Pre-made Zolimomab Aritox benchmark antibody (ADC, anti-CD5 therapeutic antibody, Anti-LEU1/T1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Zolimomab Aritox benchmark antibody (ADC, anti-CD5 therapeutic antibody, Anti-LEU1/T1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.
| Products Name (INN Index) | Pre-Made Zolimomab Aritox Biosimilar, Whole Mab Adc, Anti-Cd5 Antibody: Anti-LEU1/T1 therapeutic antibody |
|---|---|
| INN Name | zolimomab aritox |
| Target | CD5 |
| Format | ADC |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD5 |
| Package |
